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1.  INTRODUCTION 
 Helicobacter pylori(H. pylori) infection is associated with a wide 
range of gastrointestinal diseases including gastritis, peptic ulcer and 
gastric cancer. Although such infection is asymptomatic in most 
patients, it always induces an inflammatory response in the gastric 
mucosa that can be seen histologically. The most significan 
association of H. pylori is with distal gastric cancer, both intestinal 
and diffuse types, and meta-analysis has shown that infection confers 
a 2–3 fold increased chance of developing gastric cancer.1 
The World Health Organization’s international agency for 
research on cancer declared H. pylori a class I carcinogen in 1994, 
since when many studies have confirmed this association, the most 
compelling from Asia. 
PREVALENCE OF H. PYLORI& RECENT CHANGES 
Recent research has consistently shown that the prevalence of 
H. pylori is declining in the developed world and especially so in 
children suggesting thatthe infection will die out in due course. This is 
one reason put forward to suggest that population screen and treat 
may be unnecessary in these countries. However, this argument takes 
no account ofethnic groups, the effects of migration and those 
economically disadvantaged communities where infection rates are 
often much higher; therefore,a selective approach to screen and treat 
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might be considered. The importance of local differences in prevalence 
is, therefore, important, and a number of interesting studies have 
been reported this year.An excellent review relating to these issues is 
set out by Mitchell and Katelaris.2A number of original studies have 
focused on children. One study from Iceland3 studied205 children 
aged between 7 and 18 years and found only 3.4% to be infected. 
However, the prevalence was 2.6% among children where both parents 
were born in a low prevalence country compared to 17% among those 
where at least one parent had been born in a high prevalence area 
(P=.026). Seroprevalence in Icelandic adults is 30%-40%. 
Studies from Japan have also shown a considerable fall of H. 
pylori prevalence in childhood. One study from a high GC incidence 
area found only 85 of 1,765 (4.8%) students aged 13-15 years to be 
positive,4and in another the prevalence in school children aged 12-15 
years was 3.1%.5 Inoue6 reported that Japanese generations born 
before 1950 have a high prevalence of around 80%-90%, decreasing 
with age to reach around 10% or less in those born around the 
1990s,and less than 2% for those born after year 2000. Similar trends 
are seen in China where in Hangzhou7 the positivity rates were 14.8%, 
20.2%, and 25.8% in 3-6, 7-11 and 12-17 years age groups 
respectively,with the overall prevalence decreasing from 21.6% 
to17.2% between 2007 and 2014. In adults undergoing health checks 
inurban China,8 the prevalence fell from 31.9% in the1950-1959 birth 
cohort down to 20% in those born after 1990. This decrease correlated 
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with the increase in per capita gross domestic product. The prevalence 
of H. pylori has also declined in Iran9 where a meta-analysis estimates 
an overall prevalence of 54%, with a prevalence of 42% in children and 
62% in adults. Initial reports of H. pylori infection from Iran had 
earlier indicated a prevalence of more than 85%. Prevalence continues 
to decline in Sweden.10In Latvia on the other hand there has been no 
evidence of a fall in prevalence in children over the last 10 years.11 
H. PYLORI RELATED DISEASE 
Acute infection with H. pylori results in histologically proven 
gastritis clinically manifested by epigastric fullness, vomiting, soft 
stools, irritability and "putrid breath" as described by Barry Marshall 
et al in 1985 while trying to fulfill Kochs postulates with self ingestion 
of live organisms. 
This experiment was repeated in 1987 by Morris and Nicholson 
with similar results and evidence of chronic gastritis. Although 
spontaneous clearance may occur, the majority of the patients will 
develop an asymptomatic chronic state in which there is 
histologicevidence of gastritis with normal gastric acid production.12 
Infection with H. pylori has been linked to many disease states 
but data support a strong association with only a few conditions, 
which include peptic ulcer disease, gastric adenocarcinoma, and 
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gastric lymphoma.13 Other associations including the role in non-ulcer 
dyspepsia have yet to be confirmed. 
Peptic Ulcer Disease (PUD)  
H.pylori is clearly associated with both duodenal and gastric 
ulcers. Patients with H. pylori infection have been shown to have at 
least a threefold increased risk of developing duodenal ulcers.14In 
addition, approximately 90%-95% of patients with duodenal ulcers 
and 70%-90% with gastric ulcers are infected with H. pylori.13,15,16 The 
most important evidence for a causal association between H. pylori 
and PUD is that the disease process reverses upon the eradication of 
the organism. Less than 10% of patients that have received an 
effective treatment against H. pylori have recurrences compared with 
morethan 70% of those that only received acid-
suppressivetherapy.17,18The link between H. pylori and PUD has also 
been reinforced by studies done in smokers in which a twofold 
increase in the risk of ulcerative disease disappears after cure of H. 
pylori infection.19The role of H. pylori in gastric ulcers, although not 
as well studied as in duodenal ulcer disease, is similar to duodenal 
disease.17 
Although the exact pathogenesis of PUD remains unclear, the 
following hypothesis has been proposed. H. pylori causes antral 
endocrine cells to release somato statin20,21which results in 
postprandial gastrin release. This hypergastrinemic state increases 
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acid production and predisposesthe host to develop gastric 
metaplasia. Gastric metaplasiais also enhanced by concomitant risk 
factors such as smoking, alcohol, non-steroidal anti-inflammatory 
drugs (NSAID) or H. pylori pathogenic factors such as cagA or vacA 
genotype. It appears that these two genetic loci are relevant to the 
clinical consequences of H. pylori infection. 
Virtually every patient with PUD is infected with aagA positive 
strain, and vacA positivity determines the interaction with epithelial 
cells causing the inflammatory reaction and vacuolization reaction. 
Gastric adenocarninoma 
Although the incidence of gastric cancer has been declining 
worldwide since the 1930s, it is still one of the most common human 
malignancies. Evidence for an association between H. pylori infection 
and gastric cancer first came from epidemiological studies. The 
prevalenceof H. pylori infection paralleled that of gastric cancer 
indifferent populations around the world. There is a three to eightfold 
increase in the risk of gastric cancer in H. pylori infected patients. In 
addition, H. pylori infection preceded gastric cancer in other 
studies.22,23,24 About half of the malignancies involving the gastric 
body and antrum are linked to H. pylori infection but tumors arising 
in the gastroesophageal junction are not associated with this 
infection.13Individuals with infection involving the gastric body have a 
higher risk than those with infection involving the antrum. These 
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patients seem to have less dense colonization with H. pylofi and a 
state of hypochlorhydria as compared with patients with antral 
involvement.25On the other hand,most of the people with H. pylori 
infection will not develop gastric cancer. 
A recently published prospective study from Japan that 
included 1526 patients followed over an average of eightyears.26They 
found a significantly higher incidence of gastric cancer in the H. pylori 
positive patients with history of nonulcer dyspepsia, gastric ulcers, 
and hyperplastic gastric polyps, but not among those with duodenal 
ulcers. 
The pathogenesis of gastric cancer is believed to be different 
than that of PUD. It has been shown that patients with ulcerative 
disease actually have a lower incidence of gastric cancer.26,27 It is 
known that chronic epithelial injury has a carcinogenic effect in many 
tissues and is thought to be one of the mechanisms implicated in the 
development of gastric cancer in patients infected with H. pylori. This 
organism resides in the gastric mucosa and it causes chronic 
superficial gastritis. Differences in bacterial virulence and a 
combination of host factors, such as differences in the immune and 
reparative responses, may determine the ultimate outcome.28 
Inflammation will induce cell proliferation, mutation and eventually 
selection of the fittest mutant clone.13,29There is also a release of free 
radicals that can damage DNA nucleotides which will lead to 
mutations and if left unrepaired can result in metaplasia and 
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cancer.13Finally, in 1994 the World Health Organization declared H. 
pylori to be a type I carcinogen and a definite cause of cancer in 
humans.30The effect of H. pylori eradication in preventing gastric 
cancer is still unclear. Some studies have shown regression of 
preneoplastic changes in patients successfully treated for H. 
pylori,31,32 but other studies have failed to show this association.33,34 
Gastric lymphoma  
H. pylori infection appears to lead to development ofgastric 
lymphoid tissue that is not usually found in normal mucosa. This 
mucosa-associated lymphoid tissue (MALT) can undergo malignant 
transformation into a rare lowgrade B cell lymphoma of the stomach. 
This organism has been found in the majority of patients with this 
type of lymphoma35and what is even more remarkable is that 70% of 
patients with MALT lymphoma have shown to have a complete 
regression after successful treatment for H. pylori infection.36 Patients 
with large tumors or with deep invasion into the gastric wall are less 
likely to respond to therapy.34Reinfection with H. pylori can cause 
recurrence or the tumor process.37 
A causative role of H. pylori in the development of non- 
Hodgkins lymphoma of the stomach, the most common form of 
primary gastric lymphoma, has also been suggested.38Chronic 
antigenic stimulation by H. pylori has been proposed as the 
mechanism.39 
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Role in nonulcer dyspepsia 
Nonulcer dyspepsia is defined as the presence of pain or 
discomfort in the epigastrium, associated with nausea, vomiting, 
heartburn, early satiety, anorexia and belching, and with no evidence 
of structural or biochemical abnormalities in the gastric mucosa. The 
annual prevalence in western countries is approximately 25%, and it 
accounts for about 5% of office visits.40Apossible role of H. pylori in 
the etiology of this entity has been suspected since the organism was 
first linked to gastritis. However, current evidence does not seem to 
support this relationship. Some studies, including metaanalyses, have 
found a slight benefit in terms of symptomatic relief in patients who 
have received therapy against H. pylori compared with those treated 
only with acid suppressive therapy.41,42 These studies have been found 
to have methodologic weaknesses in the definition of nonulcer 
dyspepsia, the regimens used, and the documentation of H. pylori 
eradication was not well documented. A recently published meta-
analysis of seven randomized controlled trials, using combination 
therapy against H. pylori and with adequate follow-up to assess 
therapeutic response, did not find a significant trend towards a 
beneficial effect of therapy.43 
Role in other diseases 
H. pylori has been linked to several other clinical 
conditions,such as hypertrophic gastropathy, bronchiectasis, rosacea, 
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chronic urticaria, sudden infant death syndrome and coronary artery 
disease.13 Some these associations may not actually represent a 
causative effect of H. pylori and several confounding factors may be 
implicated. 
DIAGNOSIS 
Diagnostic tests for H. pylori infection can be divided into two 
categories, invasive and noninvasive methods. Invasive tests involve 
an upper gastrointestinal endoscopy with gastric mucosal biopsy and 
either rapid urease testing, histology, culture or polymerase chain 
reaction (PCR) tests. The noninvasive tests include antibody detection, 
carbon labeled urea breath tests and stool antigen detection. When 
determining the most appropriate test for a given situation, it is 
important to consider several factors including:  
1) if an endoscopy is planned for any other reasons,  
2) is it a follow-up test for a residual infection, and  
3) prior history of gastric cancer. 
Invasive diagnostic tests 
Rapid urease tests 
Rapid urease tests are relatively inexpensive assaysbased on the 
principle that a pH change brought on by ammonia produced by H. 
pylori urease is detected by the use of an indicator.44These tests are 
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highly specific and moderately sensitive.45,46Several different test 
procedures are commercially available. CLOtest derived from 
Campylobacter-like organism (Ballard Medical Products, Draper, 
Utah) employs direct placement of urease specimen on an agar gel. A 
change in color from yellow to red signifies the presence of H. pylori. 
Results are obtained about 24 h after tissue placement, although 
most reactions can be detected within 3-4 h. This test has a sensitivity 
of 75% to 95% and a specificity of 75% to 100%.47Two biopsies are 
recommended to optimize the interpretation, usually one from the 
antrum and one from the body of the stomach. Other available tests 
include PyloriTek (Serim Research Corp., Elkhart, Indiana) which uses 
a semipermeable membrane through which gaseous ammonia can 
diffuse, accelerating the reaction to about one hour with similar 
sensitivity and specificity. Also available is the hpfast (GI Suppl~ 
Camp Hill, Pennsylvania), the newest test, in which a cell-wall 
detergent is added to the agar in an attempt to improve test 
performance but clinical evaluations have demonstrated similar 
results to the CLO test. The rapid urease tests are based on the 
presence of adequate numbers of bacteria in the specimen. The 
sensitivityof these tests can be adversely affected by the recentuse of 
antibacterial agents or medications that could alter the urease 
activity, such as proton pump inhibitors (PPI) or bismuth 
compounds.46 
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ERADICATION FAILURE 
The success rate of standardor first-line drug therapy which 
consisting of amoxicillin, clarithromycin and proton pump inhibitor, is 
gradually decreasing over the last decade. First-line eradication 
therapies most commonly used in everyday clinical practice fall 
considerably short of the 80% intention-to-treat (ITT) eradication 
rates, that are considered the minimal acceptable levels as 
recommended in the Maastricht guidelines.48 The  objective of H. 
pylori treatment is to achieve 100% eradication, but till date no 
therapy achieves 100% eradication rate. Dual, triple and quadruple 
drug treatment therapy failed to eradicate completely in 5 to 50% of 
patients.49,50 
FACTORS RESPONSIBLE FOR FAILURE OF H. PYLORI 
ERADICATION THERAPY 
Recent biopsy studies51-55confirmsthatafter acquiring H. 
pyloripenetrates intothe mucus layer of the stomach and fixes itself 
with glycolipids and phospholipids of mucus gel. H. pylori, then 
disruptsepithelial layer directly or indirectly by releasingof 
certaintoxinsand enzymes.55,56For effective H. pylori eradication, 
antibiotics need to enter into the gastric mucus layer and maintain an 
effective concentration  for sufficient period of time. 
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Drugs released from conventional tablets or capsules reside 
shorter duration of time in stomach. Because of its shorter residence 
time, conventional tablets and capsules are unable to deliver the 
antibiotics into the mucous layer for sufficient period of time. This is 
one of the main reason for failure of H. pylori eradication therapy. In 
order to increase the eradication rate, it is essential to design suitable 
dosage forms to deliver the antibiotics into the site of infection.57,58Non 
compliance, bacterial resistance, cost of drugs and duration of the 
treatment also  influences the H. pylori eradication.59-61 
Antibiotic resistant H. pylori strains developed mostly due to the  
unavailability of required antibiotic concentration at the site of action 
for sufficient period of time.62It is a potentially serious problemin H. 
pylori eradication therapy.  
Conventional tablets and capsules are not delivering the 
sufficient antibiotic concentration for sufficient period of time in the 
mucus because of its shorter residence time in the stomach. In order 
to increase contact time, high doses of antibiotics are commonly 
prescribed, which causes adverse effects and, also it affects entire 
microbial flora of the gastro-intestinal tract.63,64 
DRUG DELIVERY SYSTEMS FOR GASTRIC RETENTION 
It is essential to design suitable drug delivery systems to deliver 
the antibiotics into the mucus layer where H. pylori exist.  Gastric 
Formulation and evaluation of levofloxacin hemihydrate mucoadhesive microspheres for 
eradication of Helicobacter pylori  infection 
 
Department of Pharmaceutics 13            J.K.K. Nattraja College of Pharmacy 
 
 
residence time of the dosage forms is important for delivery of drug 
into the mucus. Gastroretentive systems are commonly used to 
increase gastric residence time of dosage forms. Some of the 
gastroretentive dosage forms discussed below 
a. Floating Systems65,66 
Floating systems were mostly used to increase the gastric 
residence time of the dosage since1970. Various types of floating 
systems have been reported, such as hollow microspheres, raft-
forming systems, hydrodynamically balanced systems (HBS) and gas-
generating systems. Due to the variability in gastric transit times from 
between person to person, floating systems were not able to produce 
reproducible gastric residence time, and also these systems required 
sufficient amount of gastric fluid to allow the systems to float. 
b. Mucoadhesion 
Fixing of two surfaces is called adhesion. Adhesion of natural or 
synthetic substances into the biological material are called 
“Bioadhesion”. If the biological material is mucus the term 
“Mucoadhesion” is commonly used.67,68 
c. Mucoadhesive Systems 
Mucoadhesive systems are adhere into the mucus layer. When 
the dosage forms deliver the drug at the site of action for prolonged 
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period, usually the efficacy and bioavailability of the drug is 
increased.68Mucoadhesive systems adhere into the gastric mucus 
layer for prolonged period, and deliver the drug for sufficiently for 
longer period of time. Mucoadhesive drug delivery systems are highly 
suitable for the treatment of H. pyloriinfection, because it can deliver 
antibioticsdirectly into site of action.  
MUCOADHESIVE DRUG DELIVERY SYSTEMS  
 Mucoadhesive dosage forms adhere into the mucus layer and 
release the drug at a controlled rate. Various theories have been 
proposed to explain the mechanisms involved in bioadhesion and 
mucoadhesion.69,70 
a. Mucus: structure, function and composition 
Mucus is a viscous fluid secreted by goblet cells of the stomach. 
Mucus protects and hydrates the epithelial layer and also it prevents 
the entry of pathogens and toxic substances into the blood 
circulation.71 
b. Composition of mucus 
Glycoproteins, lipids, electrolytes and water are the main 
constituents of mucus.72The exact composition of mucus is given 
below: 
1. Water:  95% 
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2. Glycoproteins and lipids:  0.5–5% 
3. Mineral salts: 0.5–1% 
4. Free proteins: 1%.  
Depending on its site of secretion and certain disease conditions, the 
composition of the mucus may vary.71 
c. Mucin: the glycoprotein of mucus 
Glycoprotein part of the mucus is called mucin. Two forms of 
mucin are commonly found in mucus, such as membrane bound 
mucin and soluble secretory mucin.73-76Due to its high molecular 
weight and disulﬁde bridge, secretory mucins form viscous gels. 
Membrane-bound mucins contain a hydrophobic domain anchoring 
the molecules in the plasma membrane. In epithelial surfaces both 
types of mucins are foundand to protect the surface. 
Mucin consists of peptide core (10–30%) and oligosaccharide 
chains (70–80%). Both are linked linked via o-glycosidic bonds.77-
85The mucin peptide corecontains high levels ofalanine, serine,glycine, 
threonine, proline and aromatic amino acids.86-89 
Oligosaccharide part of the mucus consists of N-acetylglucosamine, 
galactose, N-acetylgalactosamine, fucose and sialic acid.89Mucus 
exhibit negative charge due to presence of sialic acid and sulfate 
residues.90 
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d.Thickness of the mucous layer and its turnover 
The thickness of mucus layer controls the rate of drug entry 
into the blood circulation.  The thickness of human stomach mucous 
layer has been reported to be 576±81 μm.91 In general, the thickness 
of mucus layer varies depending on its site of secretion and, thickness 
which varies between 50 and 450 μm.92,93 
Mucus is constantly released by goblet cells and adheres into 
the epithelial layer for specified period. Mucus is consistently removed 
from the epithelial layer by peristaltic forces. Turnover time of mucus 
has not been reported accurately, and usually it varies between 4–6 
hours.94-96 
THEORIES OF MUCOADHESION  
There are four main theories that explains the possible 
mechanisms of mucoadhesion they are given below 
1. Electronic theory 
2. Adsorption theory 
3.Wetting theory 
4. Diffusion theory.  
 
Formulation and evaluation of levofloxacin hemihydrate mucoadhesive microspheres for 
eradication of Helicobacter pylori  infection 
 
Department of Pharmaceutics 17            J.K.K. Nattraja College of Pharmacy 
 
 
a. The electronic theory 
According to this theory mucoadhesion occurs due to transfer of 
electrons between mucoadhesive polymer and mucus.97,98 
b. The adsorption theory 
 According to the adsorption theory99-103mucoadhesion occurs 
due to the formation of molecular bonding between mucoadhesive 
polymer and mucus by van der Waals forces and hydrogen bonds. 
c. The wetting theory 
 The wetting theory104-108correlatesthe surface tension of the 
mucoadhesive polymer and the mucus.  
d. The diffusion theory 
 According to this theory, mucoadhesiveness is achieved by 
interpenetration of polymer chains of mucus and mucoadhesive 
polymers.109-114 
 In addition to above motioned theories various polymer 
structure related and functional groups related factors contribute to 
varying degrees of polymer/mucus interactions. 
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FACTORS AFFECTING MUCOADHESION 
a. Functional group contribution 
Mucoadhesiveness mainly occurs due to interpenetration of 
polymer chains of mucus and mucoadhesive polymers and, formation 
of secondary bonding between mucus and mucoadhesive polymers. 
Secondary non-covalent bonding forms mainly due to hydrogen bond 
formation between mucus and hydrophilic functional groups of the 
mucoadhesive polymers such as hydroxyl (OH), carboxyl (COOH), 
sulphate groups (SO4H) and amide (NH2) groups. Polymers that have 
above motioned functional groups form high number of hydrogen 
bonds with mucus, andinteract more strongly with mucus.145 
b. Degree of hydration 
Optimal hydration of mucoadhesive polymers is essential for 
effective mucoadhesion. Hydration of the mucoadhesive polymers 
occurs due to combination of osmotic forces and capillary action 
between the mucoadhesive polymer and the mucus layer.116Hydration 
of polymer helps for relaxation of polymer chains and interpenetration 
of polymer chains. Excess hydration affects mucoadhesion due to the 
formation of a greasy mucilage.117 
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c. Polymerchain length, molecular weight and degree of cross-
linking 
Mucoadhesive nature of the mucoadhesive polymers varies 
depending upon its molecular weight. High molecular weight is 
necessary for effective mucoadhesion; however, polymer which has 
extremely long polymer chains,was unable to diffuse and 
interpenetrate into mucosal surfaces.118-121 
d. pH and charge 
pH value of the physiological  environment also  influences the 
mucoadhesive nature of the polymer.122,123Mucoadhesive nature of 
polyacrylic polymers are affected considerably by pH value of the 
physiological  environment. Carboxylic groups of polyacrylic polymers 
are essential for mucoadhesion. At low pH, these carboxylic groups 
are available in unionized state and form strong hydrogen bonding 
with mucus. At elevated pH values, carboxylic groups ionize, unable to 
form hydrogen bond with mucus. Chitosan, a positively charged 
polymer, it forms polyelectrolyte complexes with negatively charged 
mucins and exhibits strong mucoadhesion at high pH value.124 
e. Polymer concentration 
Concentration of the polymer is also considerably affects the 
strength of mucoadhesive nature of the polymer. The optimum 
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polymer concentration is varies depending upon the physical state of 
the dosage form.125 
MUCOADHESIVE POLYMERS  
The mucoadhesive polymers that are commonly used in the 
preparation of mucoadhesive dosage forms are commonly classified 
into two types. 
1. First generation mucoadhesive polymers 
2. Second generation mucoadhesive polymes 
a. First generation mucoadhesive polymers 
The firstgeneration mucoadhesive polymers are subdivided into 
three categories: 
(1). Anionic polymers 
(2). Cationic polymers and 
(3). Non-ionic polymers 
 Anionic polymers 
For the preparation of pharmaceutical formulations,anionic 
polymers are most widely used, because of its low toxicity and high 
mucoadhesive nature. Polymers which have carboxyl and sulphate 
functional groups are called anionic polymers. The most widely used 
anionic polymer is poly(-acrylic acid) (PAA).It has excellent 
mucoadhesive nature, due to the formation of strong hydrogen 
bonding with mucus126.PAA are non-toxic, non-irritant and considered 
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safe (GRAS (Generally Recognized As Safe) status) for oral use by the 
FDA.127,128 
 Cationic polymers 
Chitosan is the most widely used cationic polymer. Chitosan is 
produced by the deacetylation of chitin. Chitosan is mostly preferred 
because of its polysaccharide nature, biodegradability,biodegradability 
and less toxic nature.129Chitosan binds with mucus by ionic 
interactions mechanism. It interacts with sialic acid and sulphonic 
acid substructures of mucus. Moreover, the amino groups and 
hydroxyl also interact with mucus by hydrogen bonding.129 
 Non-ionic polymers. 
Hydroxypropylmethyl cellulose (HPMC) and Methyl cellulose 
(MC) are commonly used nonionic   polymers. Non-ionic polymers 
have less mucoadhesive property compared to polyelectrolytes 
because of its weak interactive nature with mucus.129 Mucoadhesive 
property of non ionic polymers are mainly occurs due to the 
penetration of its polymer chains into the mucus.130 
b. Second generation mucoadhesive polymers 
 Lectins 
Lectinsare made up of proteins and glycoproteins. It binds with 
carbohydrate molecules of epithelial cells reversibly.After binding with 
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cells, the lectins can either remain present on the cell surface or get 
engulfed via a process of endocytosis. Because of this nature, lectins 
are used to target the drug.  Some bacteria use lectins to fix with the 
cells of the host during infection. Lectins are not commonly used 
because of its immunogenic or anaphylaxis nature.131,132 
 Bacterial adhesions 
K99-ﬁmbriae, an attachment lectin, obtained from E. coliis most 
widelyused to target the drug into gastrointestinal tract, and also it 
covalently attaches with polyacrylic acids.133 
Recently, a new types of mucoadhesive polymer has been 
introduced into the market. These new types of mucoadhesive 
polymers are prepared by introducing thiol groups into the polymeric 
backbone of established mucoadhesive polymers. Thiol groups 
interact strongly with cysteine rich port of mucus by forming disulfide 
bonds.133These disulfide bonds are not affected by ionic strength and 
pH of the physiological environment. 
Example of thiolated polymers.134 
 Poly(acrylic acid)–homocysteine  
 Chitosan–iminothiolane 
 Poly(methacrylic acid)–cysteine 
 Chitosan–thioethylamidine  
 Poly(acrylic acid)–cysteine  
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 Chitosan–thioglycolic acid  
 Sodium carboxymethylcellulose–cysteine 
 Poly(acrylic acid)–homocysteine  
 Alginate–cysteine 
 
MUCOADHESIVE SYSTEMS IN ORAL DRUG DELIVERY 
Oral mucoadhesive drug delivery systems extend the residence 
time of dosage forms in gastric or small intestine. Mucoadhesive 
systems, commonly used to deliver the drug into the site of action, 
target the drug into certain parts of GI tract and prolong the drug 
delivery.   
A number of mucoadhesive dosage forms, including 
nanoparticles, semisolid dosage forms, microspheres, powders, 
sustained release tablets have been widely reported. 
a. Mucoadhesive microspheres 
Microsphere plays an important role in particulate drug delivery 
systems,because of its size and its good carrier property. One of the 
main drawbacks of microspheres is by its shorter gastric residence 
nature. These drawbackshave now been solved by coupling the 
mucoadhesive property to the conventional microspheres, by 
preparing novel “Mucoadhesive microspheres.” 
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Mucoadhesive microspheres are commonly prepared by using 
mucoadhesive polymers or coating of conventional microspheres with 
mucoadhesive polymers. The size of the mucoadhesive polymers 
commonly varies between 1–1000 µm.135 Mucoadhesive microspheres 
can be tailored to stay to any mucosal tissue including those found in 
urinary tract, GI tract, nasal cavity and eye. 
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2. DRUG PROFILE136 
Levofloxacin hemihydrate 
Generic and additional names Levofloxacin hemihydrate 
Synonyms BAY 12-8039 
Molecular formula C18H20FN3O4, ½ H2O 
Molecular weight 370.4 
Description LFX is a yellowish white to yellow powder 
Solubility Freely soluble in glacial acetic acid, chloroform; sparingly 
soluble in water 
Melting point 214- 216ºC 
Category Anti-Bacterial Agents, Anti-Infective Agents, Quinolones 
Phamacokinetics 
 Absorption LFX is rapidly and entirely absorbed after oral dose. 
 bioavailability 99% 
 Protein Binding 24 – 38 % 
 Excretion Urinary 
 Plasma Half Life 6 to 8 hr 
Mechanism of action 
 LFX is L form of the racemate, OFX, a quinolone antimicrobial 
agent. The antibacterial activity of OFX resides primarily in L-isomer. 
The MOA of LFX involves destroying of bacterial topoisomerase and di-
nucleotide adenosine gyrase enzymes required for di-nucleotide 
adenosine replication, transcription, repair and recombination. LFX 
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exhibits in vitro MIC of two mcg/mL or less against most (•90%) 
strains 
Dose (H.Pylori infection)137 
Levofloxacin 500 mg b.d 
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3. POLYMER PROFILE 
CARBOPOL 974P138 
Nonproprietary Names: Carbopola, Carbopols. 
Synonyms:Poly acrylic acid polymer, carbopol, acrylic acid, 
carboxyvinyl polymer, Acritamer, carboxy poly methylene. 
Structural Formula 
 
The polymer chains of carbopols are crosslinked with allyl 
pentaerythritol and polymerized in ethyl acetate. 
Description:Carbopols are white-colored, hygroscopic, fluffy powders    
Molecular Weight: 12000-140000 
Melting point:Decomposition occurs at 260ºC. 
Glass transition temperature:100 –105°C. 
Moisture content:Normal content is up to 2%.  
Solubility:Carbopol 974p insoluble in water, dilute acids, and 
common organic solvents. 
Stability:Stable though hygroscopic and can be heated at 
temperatures below 104ºC up to 2 hours without affecting their 
thickening efficiency. 
Safety:Carbopols are generally nontoxic and nonirritant. There is no  
hypersensitivity reactions are reported.  
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HYDROXYPROPYLMETHYLCELLULOSE (HPMC)139 
Non-proprietary Names:Hypromellose (BP), Hydroxypropyl methyl 
cellulose (JP), Hypromellosum (PhEur), Hypromellose (USP). 
Synonym:Tylopur, Benecel MHPC, Metolose, E464, hydroxypropyl 
methylcellulose, Methocel, methylydroxypropylcellulose HPMC. 
Chemical Name:[C6H7O2(OH)z(OCH3)x(OCH2CHOHCH3)y]n 
Description:Odorless and tasteless white creamy powder. 
Molecular Weight:10000-1500000. 
Grades:Methocel K100 Premium LVEP, Metolose 90SH, Methocel K4M 
Premium, Metolose 65SH, Methocel K15M Premium, Metolose 60SH, 
Methocel K100M, Methocel E50 Premium LV, Premium, Methocel E4M 
Premium, Methocel E15 Premium LV, Methocel F50, Methocel E6 
Premium LV, Premium Methocel E10M Premium CR, Methocel E5 
Premium LV, Methocel E3 Premium LV. 
Structural formula 
 
Where R is H, CH3, or CH3CH (OH) CH2 
Glass transition temperature:170 - 180°C. 
Moisture content:HPMC absorbs moisture from the atmosphere. 
Solubility:Soluble in cold water, practically insoluble in ethanol 
(95%), chloroform and ether.  
Viscosity:HPMC  K4M having viscosity of 4000 cps (2% w/v, at 20ºC) 
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EUDRAGIT RS 100140 
Synonyms:Polymeric methacrylates, Eastacryl 30D,  Kollicoat MAE 
30 D, Acryl-EZE, Kollicoat MAE 30 DP,  Eudragit.   
Chemical name:Poly (ethyl acrylate, methyl methacrylate, 
trimethylammonioethyl methacrylate chloride) 1: 2: 0.1 
Structural Formula 
 
Eudragit RS 100: R1=H, CH3;R2=CH3 ,C2 H5;R3=CH3;R4=CH2CH2 
N(CH3)3+Cl- 
Solubility:Soluble in acetone and dichloromethane. Insoluble in 
petroleum ether and water. 
Density (bulk):0.390 g/cm3 
Density (tapped):0.424 g/cm3 
Refractive index:1.38–1.385 for Eudragit RL and RS 
Safety:Polymethacrylate copolymers generally regarded as nontoxic 
and nonirritant materials. 
 
 
 
 
Formulation and evaluation of levofloxacin hemihydrate mucoadhesive microspheres for 
eradication of Helicobacter pylori  infection 
 
Department of Pharmaceutics 30            J.K.K. Nattraja College of Pharmacy 
 
 
4. LITERATURE REVIEW 
 Umamaheshwari et al., (2002)141 prepared acetohydroxamic acid 
entrapped floating mucoadhesive microspheres by emulsion solvent 
diffusion technique. A 2% (w/v) solution of polycarbophil was used to 
prepare floating mucoadhesive microspheres. In vitro floating studies, 
detachment force and in vivo studies were confirmed the potential of 
these microspheres. 
  
 Umamaheshwari et al., (2003)142 developed acetohydroxamic 
acid loaded polycarbonate microballoons by a solvent evaporation 
method. In simulated gastric fluid In vitro release studies were 
conducted. About 74% to 85% of microballoons were floated up to 12 
h. In vitro cell growth studies were conducted by using H. pylori 
culture and in vivo studies were conducted by using H. pylori infected 
Mongolian gerbils. Prepared microballoons demonstrated 10 times 
higher anti-H. pylori action when compared to plain acetohydroxamic 
acid solution.  
 
 Hejazi and Amiji (2003)143 developed tetracycline loaded 
chitosan microspheres for H. pylori infection. Suspensions of prepared 
microspheres were given to gerbils. Gerbils were killed at different 
time intervals to assess the radioactivity in gastric fluids and tissues. 
11% of chitosan microspheres remained in the stomach after 10 hours 
of administration. Higher tetracycline concentration was observed in 
Formulation and evaluation of levofloxacin hemihydrate mucoadhesive microspheres for 
eradication of Helicobacter pylori  infection 
 
Department of Pharmaceutics 31            J.K.K. Nattraja College of Pharmacy 
 
 
the stomach than plain drug solution and non crosslinked 
microspheres.  
 
 Schicho Higo et al., (2004)144 developed tetracycline loaded 
sucralfate acidic complex for eradication of H. pylori.  In vitro results 
confirmed that more amount of tetracycline loaded sucralfate acidic 
complex retained on the gastric mucosa than physical mixture of 
tetracycline and sucralfate.  Addition of acid during the formulation 
dissociated the aluminium hydroxide groups from the binding sites 
and produced more binding sites. 
 
  Amiji (2004)145 developed tetracycline loaded chitosan 
microspheres. Efficacy of prepared microspheres was evaluated by 
using the fasted Mongolian gerbils. Tetracycline loaded chitosan 
microspheres were given to H. pylori infection induced gerbils. A 
considerable increase in H. pylori eradication activity was observed in 
comparison to aqueous solution of the drug.   
 
 Ishak et al., (2007)146prepared metronidazole beads using 
chitosan and alginate by ionotropic gelation method. Prepared beads 
showed optimum drug entrapment efficiency, immediate buoyancy, 
and extensive drug release profile. In vivo H. pylori studies showed 
that metronidazole (dose 15 mg/kg) floating beads provided 100% H. 
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pylori clearance while the metronidazole suspension (dose 20 mg/kg) 
provided only 33.33% clearance. 
 
 Rajinikanth et al., (2008)147 developed floating gel system of 
acetohydroxamic acid. Prepared floating systems formed gel 
immediately and floated for longer period time in simulated gastric 
fluid (pH 1.2). In vivo studies confirmed the anti H. pylori activity of 
floating gel system in gerbil model. Authors concluded that the 
quantity of acetohydroxamic acid required for H. pylori eradication 
effect was very less in floating gel system than acetohydroxamic acid 
suspension.  
 
 Tan S et al., (2009)148Real-time electronic speckle pattern 
interferometry method has been applied to study the diffusion 
behavior of levofloxacin mesylate (MSALVFX) in agarose hydrogel. The 
results show that the diffusivity of solute decreases with the increase 
of concentration of agarose and adapts to Kohlrausch's law. 
Furthermore, Amsden's model, based on the retardance effect 
associated with polymer chain flexibility, was employed to simulate 
the diffusion behavior. The consistent results suggest that the 
retardance effect dominates the diffusion process of MSALFVX in 
hydrogel; moreover, polymer chain flexibility greatly affects drug 
transport within the polymer matrix. 
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 Chang et al., (2010)149 prepared berberine nanoparticles for the 
eradication of H. pylori. Chitosan  was used to prepare nanoparticles. 
The effect of the nanoparticles and their mechanisms were evaluated 
by using human gastric carcinoma epithelial cell line. The prepared 
nanoparticles significantly suppressed the H. pylori growth and 
reduced cytotoxic effects of  H. pylori. 
 
 Arora and Budhiraja (2011)150 prepared floating metronidazole 
tablets for H. pylori eradication. Tablets were prepared by using 
carbopol 971P and methocel K100LV. The floatability and drug release 
increased in the presence of sodium bicarbonate, microcrystalline 
cellulose and sodium citrate. The optimized formulation provided drug 
release up to 12 hours by anomalous diffusion mechanism. 
 
 Vasilev K et al., (2011)151 prepared plasma polymerization of n-
heptylamine for the generation of two thin coated layers that serve two 
distinct purposes. First, an n-heptylamine plasma polymer layer is 
applied onto the surface of the solid carrier material in order to 
facilitate spreading of the drug, which is applied by solvent casting; 
levofloxacin in ethanol was used for this study. A second n-
heptylamine plasma polymer coating then serves as a thin barrier 
coating to control the release. We show that the rate of release can be 
adjusted via the thickness of the plasma polymer overlayer. We also 
show that this modality of controlled release of levofloxacin completely 
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inhibits Methicillin-resistant Staphylococcus aureus (MRSA) 
colonization and biofilm formation on and near the coated biomaterial 
surface. 
 Kumar G et al.,(2012)152 prepared novel poly(lactic-co-glycolic 
acid) (PLGA)-based nanoformulation of levofloxacin for multidrug-
resistant tuberculosis with the purpose of achieving sustained release 
in plasma. After lyophilization of levofloxacin-loaded nanoparticles, 
the average size, charge, and polydispersity index were 268 ± 18 nm, -
10.2 ± 1.5 mV, and 0.15 ± 0.03, respectively. The maximum drug 
encapsulation efficiency and loading capacity were 36.9 ± 6.1% (w/w) 
and 7.2 ± 1.2 mg/100 mg nanopowder, respectively. Biphasic 
extended-release profile was produced in vitro. Scanning electron 
microscopy and Fourier transform infrared studies showed spherical 
shape of drug-loaded nanoparticles and no drug-polymer interactions 
were observed. After single oral administration in mice, levofloxacin-
loaded PLGA nanoparticles produced sustained release of levofloxacin 
for 4 days in plasma against 24 h for free levofloxacin. Levofloxacin 
was detected in organs (lung, liver, and spleen) for up to 4-6 days in 
case of levofloxacin-loaded nanoparticles, whereas free levofloxacin 
was cleared within 24 h. This novel formulation did not show any 
significant adverse effects on body weight and clinical signs in mice. 
No treatment-related changes were found in hematological and 
biochemical parameters and on histopathological evaluation. These 
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results indicate the feasibility of development of an orally efficacious 
safe formulation of levofloxacin with sustained-release properties. 
 
 El-Zahaby SA et al., (2014)153 prepared gastroretentive 
levofloxacin (LVF) floating mini-tablets for the eradication of 
Helicobacter pylori (H. pylori). They were prepared using the matrix 
forming polymer hydroxypropyl methylcellulose (HPMC K100M), alone 
or with Carbopol 940P in different ratios by wet granulation 
technique. Buoyancy of mini-tablets was achieved by an addition of an 
effervescent mixture consisting of sodium bicarbonate and anhydrous 
citric acid to some formulations. The prepared mini-tablets were 
evaluated for weight variation, thickness, friability, hardness, drug 
content, in vitro buoyancy, water uptake and in vitro release. The 
optimized formula was subjected to further studies: FT-IR, DSC 
analysis and in vivo examination in healthy volunteers. The prepared 
mini-tablets exhibited satisfactory physicochemical characteristics. 
Incorporation of gas-generating agent improved the floating 
parameters. HPMC K100M mini-tablet formulation (F1) offered the 
best controlled drug release (>8 h) along with floating lag time <1 s 
and total floating time >24 h. The obtained DSC thermograms and FT-
IR charts indicated that there is no positive evidence for the 
interaction between LVF and ingredients of the optimized formula. The 
in vivo test confirmed the success of the optimized formula F1 in being 
retained in the stomach of the volunteers for more than 4 h. LVF 
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floating mini-tablets based on HPMC K100M is a promising 
formulation for eradication of H. pylori. 
 
 El-Zahaby SA et al., (2014)154 prepared size increasing (plug-
type) levofloxacin hemihydrate (LVF) tablets for eradication of 
Helicobacter pylori (H. pylori). They were prepared using in situ gel 
forming polymers including: gellan gum, sodium alginate, pectin and 
xanthan gum. Effect of cross-linkers: calcium and aluminum chloride, 
on the drug release was also studied. The prepared tablets were 
evaluated for their physicochemical parameters: weight variation, 
thickness, friability, hardness, drug content, water uptake and in vitro 
drug release. The optimized formula was subjected to further studies 
such as radial swelling test, FT-IR and DSC. Results revealed that LVF 
release depends not only on the nature of the matrix but also on the 
type of cross linker used to form this polymeric matrix. The addition of 
either calcium chloride or aluminum chloride, as cross-linkers, to 
gellan gum formulations significantly decreased drug release. Other 
polymers' formulations resulted in increased drug release upon 
addition of the same cross-linkers. The formula containing xanthan 
gum without any cross linker showed the most sustained LVF release 
with an increase in diameter with time, thus acting as a plug-type 
dosage form. IR spectra and DSC thermograms of LVF, xanthan gum, 
and a physical mixture of both, indicated that there was no 
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interaction between the drug and the polymer and confirmed the drug 
stability. 
 
 Merchant Z et al., (2014)155prepared powders by spray-drying 
from an aqueous solution containing levofloxacin and 
chitosan/amphiphilic octanoyl chitosan. l-leucine was also used to 
assess its effect on aerosolization. Following spray-drying, the 
resultant powders were characterized using scanning electron 
microscopy, laser diffraction, dynamic light scattering, HPLC, 
differential scanning calorimetry, thermogravimetric analysis and X-
ray powder diffraction. The in vitro aerosolization profile was 
determined using a Next Generation Impactor, whilst in vitro 
antimicrobial assessment was performed using MIC assay. 
Microparticles of chitosan have the property of mucoadhesion leading 
to potential increased residence time in the pulmonary mucus, 
making it important to test the toxicity of these formulations. In-vitro 
cytotoxicity evaluation using MTT assay was performed on A549 cell 
line to determine the toxicity of formulations and hence feasibility of 
use. The MTT assay confirmed that the polymers and the formulations 
were non-cytotoxic. Hydrophobically modifying chitosan showed 
significantly lower MIC (4-fold) than the commercial chitosan against 
P. aeruginosa. The powders generated were of suitable aerodynamic 
size for inhalation having a mass median aerodynamic diameter less 
than 4.5μm for formulations containing octanoyl chitosan. These 
highly dispersible powders have minimal moisture adsorption and 
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hence an emitted dose of more than 90% and a fine particle fraction 
(FPF) of 52%. Powders with non-modified chitosan showed lower 
dispersibility, with an emitted dose of 72% and FPF of 20%, as a 
result of high moisture adsorption onto the chitosan matrix leading to 
cohesiveness and subsequently decreased dispersibility. 
 
 Jalvandi J et al., (2017)156 prepared a range of biodegradable 
drug-nanofibres composite mats drug delivery systems. The results 
showed that controlled release of levofloxacin (LVF) could be achieved 
by covalently binding LVF to low molecular weight chitosan (CS) via a 
cleavable amide bond and then blending the conjugated CS with 
polyvinyl alcohol (PVA) nanofibres prior to electrospinning. PVA/LVF 
and PVA-CS/LVF nanofibres were fabricated as controls. The 
conjugated CS-LVF was characterized by FTIR, DSC, TGA and 1H 
NMR. Scanning electron microscopy (SEM) showed that the blended 
CS-PVA nanofibres had a reduced fibre diameter compared to the 
controls. Drug release profiles showed that burst release was 
decreased from 90% in the control PVA/LVF electrospun mats to 27% 
in the PVA/conjugated CS-LVF mats after 8h in phosphate buffer at 
37°C. This slower release is due to the cleavable bond between LVF 
and CS that slowly hydrolysed over time at neutral pH. The results 
indicate that conjugation of the drug to the polymer backbone is an 
effective way of minimizing burst release behaviour and achieving 
sustained release of the drug, LVF. 
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 Zhang LP et al., (2018)157 prepared liquid crystalline molecularly 
imprinted polymers (LC-MIPs) by low cross-linking. The multiwalled 
carbon nanotubes (MWCNTs) coated LC-MIP (MWCNT@LC-MIP) was 
the first fabricated as a novel floating interaction-controlled DDS. The 
synthesis was achieved by adding 9-vinylanthracene to obtain the 
high-density vinyl group functionalized MWCNTs firstly, and then 
polymerization of LC MIPs was performed on the surface of MWCNTs 
using a mixture of methacrylic acid, ethylene glycol dimethacrylate, 
and 4-methyl phenyl dicyclohexyl ethylene (LC monomer) with 
levofloxacin (LVF) as model template drug. Both template/functional 
monomer ratio and levels of crosslinker were optimized to obtain the 
best imprinting factor. Characterizations of polymer were investigated 
by the transmission electron microscope, nitrogen adsorption, 
thermogravimetric analysis. The release profiles showed an obvious 
zero-order release of LVF from MWCNT@LC-MIP, which exhibited 3.8 
μg/h of the release rate with duration of about 20 h. In vivo 
pharmacokinetic study displayed the relative bioavailability of the 
gastro-floating MWCNT@LC-MIP was 578.9%, whereas only 58.0% of 
MWCNT@MIP and 11.7% of the bared MWCNT. As a conclusion, 
MWCNT@LC-MIP showed potentials for oral administration by the 
innovative combination of floating and controlled release properties. 
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5. AIM AND OBJECTIVES OF THE WORK 
Helicobacter pylori (H. pylori) causes chronic gastritis, peptic 
ulcer, gastric cancer and gastric MALT lymphoma. Guidelines support 
treatment irrespective of symptoms and complications. Success rates 
of empirical therapies have fallen in recent years in many 
countries.The “key” antibiotics in the treatment of H. pylori infection 
are clarithromycin and levofloxacin. After failure of an empirical first-
line treatment, physicians use a levofloxacin tripletherapy (PPI + 
levofloxacin + amoxicillin) or a bismuth quadruple therapy (6-8). 
Inparticular, levofloxacin triple therapy is the treatment of choice after 
failure ofbismuth quadruple therapy. Even though, treatment fails to 
eradicate H. pylori infection completely. The main reasons given for 
the treatment failure are the short residence time of antimicrobial 
agents in the stomach and availability of insufficient antimicrobial 
concentration in the mucus layer of the stomach where H. 
pyloriresides, emergence of antibiotic-resistant strains and poor 
adherence possible due to complicated regimens and drug-related 
side-effects. 
 
It is therefore, essential to design suitable dosage forms that not 
only solve the limitations of conventional delivery systems but also 
deliver the antibiotics to the site of action. To improve treatment of H. 
pylori infection, by achieving required bactericidal concentrations of 
antibiotics in the stomach, it is assumed that the novel formulations 
Formulation and evaluation of levofloxacin hemihydrate mucoadhesive microspheres for 
eradication of Helicobacter pylori  infection 
 
Department of Pharmaceutics 41            J.K.K. Nattraja College of Pharmacy 
 
 
adhering to the mucus layer and releasing the drug at the site of 
infection would be significantly more effective than conventional 
dosage forms. Mucoadhesive drug delivery systems may prolong the 
gastric residence time of the antibiotics because they adhere to the 
mucus and also deliver the antibiotics directly into the mucus where 
H. pylori exists. Among the mucoadhesive drug carriers, 
mucoadhesive microspheres have some advantages because of its 
close contact with the mucus, lightweight and smaller dose variation. 
Hence, in this study, mucoadhesive microsphere drug delivery system 
was selected to deliver levofloxacin effectively into the mucus. 
 
Aim 
The aim of the present research work is to formulate and 
evaluate mucoadhesive microspheres of levofloxacin by using the 
ucoadhesive polymers for H. pylori eradication. 
 
Objectives of the present work is to 
1. Deliver the antibiotics at the site of infection. 
2. Prolong the delivery of the antibiotics at the site of infection.  
3. Minimize the dosing frequency. 
4. Reduce the amount of drug required for H. pylori eradication. 
5.  Minimize of side effects associated with levofloxacin. 
6. Reduce the duration of treatment. 
7. Develop optimized dosage form to improve patient compliance.  
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To achieve the above therapeutic needs effectively, the drug 
delivery system should have mucoadhesive and extended release 
property. To achieve the mucoadhesive and extended release property 
in this study, combination of mucoadhesive polymers, such as 
carbopol 974P and Hydroxy Propylmethyl cellulose K4M (HPMC K4M) 
were used. Eudragit RS 100 used as matrix polymer. 
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6.  MATERIALS AND INSTRUMENTS 
a. Materials 
S.No Materials Supplier 
1 Acetone SD Fine chemicals, Mumbai. 
2 
Levofloxacin 
hemihydrate 
Goldsun Pharmaceuticals limited, 
Mumbai. 
3 Carbopol 974P 
Macleods Pharmaceuticals limited, 
Mumbai. 
4 Eudragit RS100 
Macleods Pharmaceuticals limited, 
Mumbai. 
5 HPMC K4M 
Macleods Pharmaceuticals limited, 
Mumbai. 
6 Hydrochloric acid Qualigens fine chemicals, Mumbai. 
7 Light liquid paraffin SD Fine chemicals, Mumbai. 
8 Methanol Merck specialties pvt. Ltd. Mumbai. 
9 n-Hexane SD Fine chemicals, Mumbai. 
10 Sodium Hydroxide SD Fine chemicals, Mumbai. 
11 Span 80 SD Fine chemicals, Mumbai. 
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b. Instruments and apparatus 
S.No 
Name of the 
Instrument 
Name of the Manufacturer 
and Model 
1 
Differential scanning 
calorimeter 
Universal Instruments. (Model: 
V4.2E TA) 
2 Digital balance 
Shimadzu Scientiﬁc 
Instruments. (Model: BL-220H) 
3 
Dissolution test 
apparatus 
Labindia. (Model: Disso 2000) 
4 FTIR Spectrophotometer 
Shimadzu, Japan. (Model:FTIR-
84005) 
5 Glass wares 
Sigma Scientific Glass Pvt. 
Ltd,Chennai. 
6 
Laboratory 
shaker/vibrator 
Xi'an Depai Biotechnology Co., 
Ltd.( Model:  BILON-COS-100B) 
7 Magnetic stirrer 
REMI Laboratory Instruments. 
(Model: 2 MLH). 
8 
Mechanical stirrer with 
Digital rpm display 
REMI Laboratory Instruments. 
(Model: RQ-121/D). 
9 Particle size Analyzer 
Particle sizing systems, Inc, 
Santa Barbara, Calif., USA 
(Model: 780 AccuSizer) 
10 
Scanning Electron 
Microscope 
Hitachi High-Technologies. 
(Model: S – 450). 
11 Stability chamber 
REMI Laboratory 
Instruments.(Model: Remi CHM- 
10 S®) 
12 
Tablet disintegration test 
machine (I.P. STD. 1985)  
Scientechinstruments.Delhi. 
13 
UV/Visible double beam 
Spectrophotometer 
Shimadzu Analytical (India) Pvt. 
Ltd. 
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14 Vacuum dryer 
Saga Engineering Co (Model:SO-
150) 
15 Vortex mixer 
Alfa Medical instruments 
(Model:RX3 Vortex mixer) 
16 
X-ray powder 
diffractometer 
Bruker AXS. (Model: D8 
Advance diffractometer). 
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7. METHODOLOGY 
PREFORMULATION STUDIES 
Standard curve of Levofloxacin hemihydratein 0.1 N HCl 
Stock solution of Levofloxacin hemihydrate(100 µg/ml) was 
prepared in 0.1 N HCl, repeated three consecutive days and each day 
in triplicate to find the inter- and intra-day variations. It was further 
diluted to obtain the known standard solutions in range of 1-10 
µg/ml. Absorbance was measured spectrophotometrically (Shimadzu 
UV/Visible spectrophotometer 2100; Tokyo, Japan) at 293 nm. The 
mean data (n=9) were used for the preparation of calibration curve. 
The concentration of the dissolved drug was calculated from 
regression equation obtained from calibration curve. 
FORMULATION OF MUCOADHESIVE MICROSPHERES 
Microspheres were prepared by emulsionsolvent evaporation 
method.158,159 Liquid paraffin and acetone were used as solvent 
system. 0.75% w/v Span80 was used to prevent agglomeration of 
microspheres during preparation.Weighed quantity ofLevofloxacin 
hemihydrateand Eudragit RS 100 was dissolved in 30 ml 
acetone.Carbopol 974P and HPMC K4M were dispersed in it. This 
dispersion was cooled to 5°C, and added slowly into 300 ml of liquid 
paraffin, which was previously cooled to 5°C,160,161with 
stirring(700rpm).  The resulting emulsion was stirred at 40°C for 40 
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min. Finally, the suspension of microspheres were filtered and washed 
by using n-hexane and the prepared microspheres were dried by 
usingvacuum dryer at room temperature overnight. 
 
Formulation composition of the mucoadhesive microspheres of 
Levofloxacin hemihydrate 
 
Formulation 
code 
Eudragit 
RS 100 
(% w/v) 
Carbopol 
974P 
(% w/v) 
HPMC K4M 
(% w/v) 
Levofloxacin 
hemihydrate 
(% w/v) 
LM1 2 1 1 5 
LM2 4 1 1 5 
LM3 6 1 1 5 
LM4 8 1 1 5 
LM5 6 0.5 1 5 
LM6 6 1.5 1 5 
LM7 6 2 1 5 
LM8 6 1 0.5 5 
LM9 6 1 1.5 5 
LM10 6 1 2 5 
 
 
 
EVALUATION OF MUCOADHESIVE MICROSPHERES 
 Determination of percentage yield of microspheres162 
Dried microspheres were collected and weighed accurately using 
a digital balance. The percentage yield of prepared microspheres was 
calculated by using the formula mentioned below: 
Percentage yield of microspheres= Weight of microspheres of obtainedTotal weight of drug and polymers  x 100 
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Determination of drug content and encapsulation efficiency163 
The drug content of the microspheres were measured by 
extraction method. Accurately weighed 5 mg of mucoadhesive 
microspheres were crushed in to a powder using glass mortar and 
pestle. The resulting powdered mucoadhesive microspheres were 
dispersed in 15 ml of 0.03 M sodium hydroxide solution. The final 
suspension was vortexed at 2500 rpm for 1 minute and then for a 
further 2 hours at 1000 rpm and room temperature. In order to 
calculate the amount of drug entrapped in the mucoadhesive 
microspheres, the suspensionwas then ﬁltered through a 0.45µm 
syringe ﬁlter and the ﬁltrate was analyzed by HPLC.164 
Drug content in microspheres= Weight of drug in microspheresWeight of microspheres  x 100 
Encapsulation efficiency= Actual drug encapsulatedTheoretical drug encapsulated  x 100 
Particle size analysis 
Particle size of the drug, excipients and prepared microspheres 
were measured by using laser based particle size analyzer (780 
AccuSizer,Particle sizing systems Inc, USA). The particles were 
dispersed in n-Hexane, and suspended mechanically by magnetic 
stirring during the analysis. 
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Shape and surface characterization 
 The shape and surface characteristics of the microspheres were 
observed under a Scanning Electron Microscope (SEM). HITACHI-SEM 
MODEL S – 450 model scanning electron microscope was used for the 
study. The prepared microspheres were placed directly on to the SEM 
sample holder by using double-sided fixing tape and coated with gold 
film (thickness 200 nm) under reduced pressure (0.001 torr) and 
photographed. 
In vitro evaluation of mucoadhesiveness165 
A periodic acid/Schiff (PAS) colorimetric method reported 
by Mantle and Allen166was used to determine the free mucin 
concentration in order to assess the amount of mucin 
adsorbed on the Levofloxacin hemihydrate mucoadhesive 
microspheres and its effect on the assessment of mucoadhesive 
behavior of prepared mucoadhesive microspheres. 
Two reagents were prepared. Schiff reagent contained 100 mL of 
1% basic fuchsin (pararosaniline) aqueoussolution and 20 mL of 1 M 
HCl. Sodium metabisulphite (0.1g) was added to every 6 mL of Schiff 
reagent before use, andthe resultant solution was incubated at 37°C 
until it becamecolorless or pale yellow. Periodic acid reagent was 
freshlyprepared by adding 10 µL of 50% periodic acid solution to 7mL 
of 7% (vol/vol) acetic acid solution.Standard calibration curves were 
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prepared from 2 mL ofmucin standard solutions (0.25, 0.5, 0.75, and 
1 mg/2 mL). 
After adding 0.2 mL of periodic acid reagent, the sampleswere 
incubated at 37°C for 2 hours in a water bath. Then, 0.2mL of Schiff 
reagent was added at room temperature. Thirtyminutes later, the 
absorbance of the solution was recorded at555 nm in a UV 
spectrophotometer (Spectronic 20D). 
Triplicate samples were run. All the samples were determined 
with the same procedure. The mucin content was calculated from the 
standard calibration curve. As comparison,the mucoadhesive potential 
of EC microspheres was alsoassessed with the above procedure. Each 
experiment wasperformed 3 times and standard deviation noted. 
Adsorption of Mucin on Chitosan Microspheres 
Mucin aqueous solution with different concentrations 
(0.025,0.05,0.1, 0.2, and 0.5 mg/mL) were prepared. Levofloxacin 
hemihydrate mucoadhesive microspheres(20 mg) weredispersed in the 
above mucin solutions, vortexed, and shaken at room 
temperature.167Then, thedispersions were centrifuged at 4000 rpm for 
2 minutes, and the supernatant wasused for the measurement of the 
free mucin content. The dataobtained were interpreted usingfollowing  
Freundlichor Langmuirequations describing the adsorption isotherms: 
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Where Cads is the concentration of mucin adsorbed at 
equilibrium and Ce is the concentration of free mucin at 
equilibrium.Values of different constants were obtained from the 
graphsof the above equations. For the Langmuir equation, 1/Cadswas 
plotted against 1/Cfree to get the constants and for theFreundlich 
equation, log Cads was plotted against Cfree to getthe constants. 
Compatibility studies 
Fourier-Transform Infrared Spectrophotometry (FTIR)  
 Infrared red spectra for pure Levofloxacin hemihydrate,blank 
microspheres, Levofloxacin hemihydrate mucoadhesive microspheres 
were obtained on a FTIR-[Shimadzu (84005)] spectrophotometer using 
the potassium bromate disk method. 200mg potassium bromate was 
used for the analysis of 2mg of sample. The scanning range was set 
into 450–4000 cm-1. 
Differential scanning calorimeter   (DSC) 
 The thermal analysis of pure drug, formulations and blank 
microspheres were carried out using Universal V4.2E TA instruments, 
to evaluate possible drug-polymer interaction.3mg of sample was 
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accurately weighed and placed in a 40-μl aluminum pan and sealed 
with a punched lid. A temperature range of 10–300oC was scanned 
using a heating rate of 10oC min-1. A nitrogen purge of 50ml min-1 was 
used in the oven. 
 X-ray powder diffractometry 
X-ray powder diffractometry (XRD) study was conducted to 
study the effect of the formulation process on the crystalline nature of 
the drug. Powder XRD patterns were recorded on a Bruker AXS D8 
Advance diffractometer using Ni-filtered, Cu K[alpha] radiation with 
2[theta] interval defined from 20 to 95[degrees] with a step size of 
0.05[degrees]. The XRD patterns of pure drug, polymers, formulations 
and blank microspheres were recorded. 
In vitro dissolution studies168,169 
 In vitro drug release from mucoadhesive microspheres was 
analyzed by using USP dissolution test apparatus 2 (Paddle) with 
stirrer at 100 rpm (Disso 2000, Labindia). Predetermined quantities of 
microspheres were placed in bowel. 900 ml of 0.1N HCl (pH 1.2) was 
used as the dissolution media. Dissolution studies were conducted at 
37ºC±0.2°C. Samples were taken at suitable time intervals and 
replaced with the same quantity of fresh dissolution medium. 
Collected samples filtered through 0.45µm syringeabsorbance was 
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measured spectrophotometrically (Shimadzu UV/Visible 
spectrophotometer 2100; Tokyo, Japan) at 293 nm. 
Kinetics of drug release 
 In order to know the drug release mechanism and in-vitro drug 
release kinetics various kinetic models were used. Zero order, first 
order, Higuchi’s,170 Peppa’s171modelswere used in this studyand  
regression coefficient values (R2) was calculated and analyzed. 
Accelerated stability testing according to ICH Q1A (R2)172 
The optimized formulation (LM6) were stored in a stability 
chamber (Remi CHM- 10 S®, India) at 40 ± 2°C and humidity of 75 ± 
5% RH for 6 months and examined for the drug content, 
mucoadhesiveness and in vitro drug release  0, 30, 90, and 180 days. 
The zero time samples were used as controls. 
Statistical analysis 
 The data obtained from the production yield, encapsulation 
efficiency, particle size, in vitro release studies and in vivo studies of 
microspheres were analyzed statistically by one-way ANOVA using 
GraphPad Prism software (GraphPad Software) and P < 0.05 was 
considered statistically significant. 
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8. RESULTS 
 
Table 1: Standard curve of Levofloxacin hemihydrate in 0.1 N HCl 
S.No 
Concentration 
(μgm/ml) 
Absorbance 
 
1 0 0 
2 1 0.011 
3 2 0.023 
4 3 0.031 
5 4 0.040 
6 5 0.052 
7 6 0.061 
8 7 0.073 
9 8 0.082 
10 9 0.092 
11 10 0.110 
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Figure 1: Standard curve of Levofloxacin hemihydratein 0.1 N HCl 
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PERCENTAGE YIELD 
 
Table 2: Percentage yield of Levofloxacin hemihydrateloaded 
mucoadhesive microspheres 
S.No Formulation code 
Percentage yield 
(Mean of three 
values ± SD) 
1 LM1 35.10±1.33 
2 LM2 61.37±1.45 
3 LM3 81.16±1.35 
4 LM4 82.10±1.78 
5 LM5 78.29±1.91 
6 LM6 82.31±1.48 
7 LM7 85.15±1.37 
8 LM8 79.52±1.81 
9 LM9 89.51±1.88 
10 LM10 92.20±1.97 
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Figure 2:  Percentage yield of Levofloxacin hemihydrateloaded 
mucoadhesive microspheres (Bars represent mean of                          
three values ± SD) 
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DRUG CONTENT 
 
Table 3: Drug content of levofloxacin hemihydrate loaded 
mucoadhesive microspheres 
 
S.No 
Formulation 
code 
Theoretical drug 
content (%) 
Practical drug 
content (%) 
(Mean of three 
values ± SD) 
1 LM1 55.60 29.64±0.42 
2 LM 2 45.45 26.56±0.33 
3 LM 3 38.46 25.58±0.82 
4 LM 4 33.33 27.55±0.32 
5 LM 5 40.00 24.56±0.41 
6 LM 6 37.04 25.85±0.34 
7 LM 7 35.71 25.45±0.65 
8 LM 8 40.00 25.95±0.44 
9 LM 9 37.04 25.98±0.49 
10 LM 10 35.71 25.60±0.61 
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Figure 3: Drug content of Levofloxacin hemihydrateloaded 
mucoadhesive microspheres (Bars represent mean of                          
three values ± SD) 
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ENCAPSULATION EFFICIENCY 
 
Table 4: Encapsulation efficiency of Levofloxacin hemihydrate 
loaded mucoadhesive microspheres 
 
S.No Formulation code 
Percentage drug 
loaded 
(Mean of three 
values ± SD) 
1 LM1 52.31±1.16 
2 LM 2 60.22±1.92 
3 LM 3 69.04±1.55 
4 LM 4 86.33±0.67 
5 LM 5 65.41±1.14 
6 LM 6 72.81±0.19 
7 LM 7 74.49±1.72 
8 LM 8 67.62±1.14 
9 LM 9 73.11±1.51 
10 LM 10 75.05±1.81 
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Figure 4: Encapsulation efficiency of Levofloxacin hemihydrate 
mucoadhesive microspheres (Bars represent mean of                               
three values ± SD) 
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PARTICLE SIZE DISTRIBUTION 
 
Table 5: Particle size distribution of Levofloxacin 
hemihydrateloaded mucoadhesive microspheres 
 
S.No Formulation code 
Particle size 
(μm) 
(Mean of three 
values ± SD) 
1 LM1 141.17±10.38 
2 LM 2 223.61±12.76 
3 LM 3 291.57±14.85 
4 LM 4 543.91±18.94 
5 LM 5 235.59±9.98 
6 LM 6 362.48±6.52 
7 LM 7 402.40±10.25 
8 LM 8 241.37±11.72 
9 LM 9 362.23±9.72 
10 LM 10 422.11±9.62 
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Figure 5: Particle size distribution of Levofloxacin hemihydrate 
loaded mucoadhesive microspheres (Bars represent mean of        
three values ± SD) 
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SCANNING ELECTRON MICROSCOPY (SEM) 
 
 
SEM photograph of prepared mucoadhesive microspheres of  
levofloxacin hemihydrate 
 
 
 
 
 
Figure 6: SEM photograph of formulation LM1 
 
 
 
 
 
Figure 7: SEM photograph of formulation LM2 
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Figure 8: SEM photograph of formulation LM3 
 
 
 
 
 
 
 
 
Figure 9: SEM photograph of formulation LM4 
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Figure 10:  SEM photograph of formulation LM5 
 
 
 
 
Figure 11:  SEM photograph of formulation LM6 
 
 
 
Formulation and evaluation of levofloxacin hemihydrate mucoadhesive microspheres for 
eradication of Helicobacter pylori  infection 
 
Department of Pharmaceutics 67            J.K.K. Nattraja College of Pharmacy 
 
 
 
 
Figure 12: SEM photograph of formulation LM7 
 
 
 
 
 
 
 
 
 
 
Figure 13: SEM photograph of formulation LM8 
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Figure 14: SEM photograph of formulation LM9 
 
 
 
 
 
 
 
 
 
Figure 15: SEM photograph of formulation LM10 
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MUCOADHESIVENESS EFFICIENCY 
 
Table 6: Mucoadhesiveness efficiency of levofloxacin hemihydrate 
loaded mucoadhesive microspheres 
 
S.No Formulation code 
Percentage of 
Mucoadhesiveness 
(Mean of three values 
± SE) 
1 LM1 61.11±0.81 
2 LM 2 62.09±0.42 
3 LM 3 63.33±0.64 
4 LM 4 68.57±0.41 
5 LM 5 53.55±0.57 
6 LM 6 75.47±0.27 
7 LM 7 86.54±0.81 
8 LM 8 59.35±0.39 
9 LM 9 69.20±0.47 
10 LM 10 72.10±0.61 
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Figure 16: Mucoadhesiveness efficiency of levofloxacin 
hemihydrate loaded mucoadhesive microspheres (Bars represent 
mean of three values ± SE) 
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COMPATIBILITY STUDIES  
 
 FOURIER TRANSFORM INFRARED SPECTROPHOTOMETRY 
(FTIR) STUDIES 
 
 
 
Figure 17: FTIR spectra of Levofloxacin hemihydrate 
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Figure 18:FTIR spectra of Blank mucoadhesive microspheres 
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Figure 19: FTIR spectra of Levofloxacin hemihydrateloaded 
mucoadhesive microspheres 
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Table 7:  Characteristic IR bands of Levofloxacin hemihydratein 
mucoadhesive microspheres. 
 
Principle peaks 
Levofloxacin 
hemihydrates 
(cm-1) 
Levofloxacin 
hemihydrate loaded 
microspheres 
–COOH monomeric 
stretching and 
bonding 
3269 and 1045 
cm-1 
All the 
above peaks are 
present in drug-loaded 
formulations that 
confirm the presence 
of drug in the polymer 
without any 
interaction. 
alkanes –CH3 and 
aromatic rings 
2846 and 1618 
cm-1 
C=O 
stretching vibration of 
the COOH group 
1721 
C–F 835 
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DIFFERENTIAL SCANNING CALORIMETERY (DSC) STUDIES 
 
 
 
Figure 20: DSC spectra of Levofloxacin hemihydrate 
 
The DSC thermogram of LVFshowed endothermic transitions at 
94.2ºC and 237.2 ºC due to the decomposition of LVF 
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Figure 21: DSC spectra of blank microspheres 
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Figure 22: DSC spectra of Levofloxacin hemihydrate loaded 
mucoadhesive microspheres 
 
 
Melting peaks of Levofloxacin hemihydrate not observed in the DSC 
profile of Levofloxacin hemihydrate loaded mucoadhesive 
microspheres, suggesting a good dispersion of the Levofloxacin 
hemihydrate in an amorphous state in microspheres. 
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 X-RAY POWDER DIFFRACTOMETRY (XRD) STUDIES 
 
 
 
Figure 23: XRD spectra of Levofloxacin hemihydrate 
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Figure 24: XRD spectra of carbopol 974P 
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Figure 25: XRD spectraof HPMC K4M 
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Figure 26:  XRD spectra of Eudragit RS 100 
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Figure 27:   XRD spectra of Levofloxacin hemihydrate loaded 
mucoadhesive microspheres 
 
 
No peaks associated with the Levofloxacin hemihydrate were observed 
in the XRD patterns Levofloxacin hemihydrate loaded mucoadhesive 
microspheres, suggesting that the antibiotic couldbe molecularly 
dispersed within the matrix in an amorphousstate. 
 
 
 
 
 
 
IN VITRO DISSOLUTION STUDIES 
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Table 8: In vitro release profile of Levofloxacin hemihydrate 
loaded mucoadhesive microspheres (Formulation LM1) 
 
 
*Each reading is an average of three determinations 
         **Standard deviation of three determinations 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Time (hours) 
Cumulative 
Percentage drug  
Released* 
 
Standard Deviation** 
0 0 0 
1 52.08 1.16 
2 80.33 1.21 
3 99.62 0.34 
4 - - 
5 - - 
6 - - 
7 - - 
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Figure 28:  In vitro release profile of Levofloxacin hemihydrate 
loaded mucoadhesive microspheres (Formulation LM1)                   
(Bars represent mean of three values ± SD) 
 
 
 
 
 
 
 
 
 
 
Table 9: In vitro release profile of Levofloxacin hemihydrate 
loaded mucoadhesive microspheres (Formulation LM2) 
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*Each reading is an average of three determinations 
**Standard deviation of three determinations 
 
 
 
 
 
 
 
Time (hours) 
Cumulative Percentage 
drug  Released* 
 
Standard Deviation** 
0 0 0 
1 45.61 1.15 
2 64.07 2.06 
3 81.29 1.32 
4 99.25 0.19 
5 - - 
6 - - 
7 - - 
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Figure 29:  In vitro release profile of Levofloxacin hemihydrate 
loaded mucoadhesive microspheres (Formulation LM2)                 
(Bars represent mean of three values ± SD) 
 
 
 
 
 
Table 10: In vitro release profile of Levofloxacin hemihydrate 
loaded mucoadhesive microspheres (Formulation LM3) 
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*Each reading is an average of three determinations 
                 **Standard deviation of three determinations 
 
 
 
 
 
 
 
 
 
 
 
 
Time (hours) 
Cumulative Percentage 
drug  Released* 
 
Standard Deviation** 
0 0 0 
1 32.15 2.31 
2 52.16 2.18 
3 66.67 1.34 
4 82.03 1.84 
5 99.73 0.14 
6 - - 
7 - - 
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Figure 30:  In vitro release profile of Levofloxacin hemihydrate 
loaded mucoadhesive microspheres (Formulation LM3)                  
(Bars represent mean of three values ± SD) 
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Table 11: In vitro release profile of amLevofloxacin hemihydrate 
oxicillin trihydrate loaded mucoadhesive microspheres 
(Formulation LM4) 
 
 
*Each reading is an average of three determinations 
                  **Standard deviation of three determinations 
 
 
 
 
 
Time (hours) 
Cumulative 
Percentage drug  
Released* 
 
Standard Deviation** 
0 0 0 
1 23.12 1.58 
2 40.52 1.96 
3 51.62 1.70 
4 63.59 2.18 
5 74.58 1.39 
6 85.61 1.75 
7 96.07 1.02 
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Figure 31:  In vitro release profile of Levofloxacin hemihydrate 
loaded mucoadhesive microspheres (Formulation LM4)                    
(Bars represent mean of three values ± SD) 
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Table 12:  In vitro release profile of Levofloxacin 
hemihydrateloaded mucoadhesive microspheres (Formulation 
LM5) 
 
 
*Each reading is an average of three determinations 
                 **Standard deviation of three determinations 
 
 
 
 
 
 
 
 
Time (hours) 
Cumulative 
Percentage drug  
Released* 
 
Standard Deviation** 
0 0 0 
1 51.13 1.69 
2 67.28 1.78 
3 83.41 2.37 
4 99.78 0.08 
5 - - 
6 - - 
7 - - 
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Figure 32:  In vitro release profile of Levofloxacin hemihydrate 
loaded mucoadhesive microspheres (Formulation LM5)                
(Bars represent mean of three values ± SD) 
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Table 13:  In vitro release profile of Levofloxacin hemihydrate 
loaded mucoadhesive microspheres (Formulation LM6) 
 
 
*Each reading is an average of three determinations 
                 **Standard deviation of three determinations 
 
 
 
 
Time (hours) 
Cumulative 
Percentage drug  
Released* 
 
Standard Deviation** 
0 0 0 
1 30.01 1.61 
2 45.63 1.22 
3 63.67 1.09 
4 71.81 2.61 
5 84.22 2.05 
6 99.62 0.23 
7 - - 
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Figure 33:  In vitro release profile of Levofloxacin 
hemihydrateloaded mucoadhesive microspheres (Formulation 
LM6) (Bars represent mean of three values ± SD) 
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Table 14: In vitro release profile of Levofloxacin 
hemihydrateloaded mucoadhesive microspheres (Formulation 
LM7) 
 
 
*Each reading is an average of three determinations 
                  **Standard deviation of three determinations 
 
 
 
Time (hours) 
Cumulative Percentage 
drug  Released* 
 
Standard Deviation** 
0 0 0 
1 26.51 1.25 
2 33.73 1.22 
3 52.25 2.68 
4 63.84 2.78 
5 74.08 2.27 
6 85.15 1.65 
7 99.68 0.28 
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Figure 34:  In vitro release profile of Levofloxacin hemihydrate 
loaded mucoadhesive microspheres (Formulation LM7) (Bars 
represent mean of three values ± SD) 
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Table 15: In vitro release profile of Levofloxacin hemihydrate 
loaded mucoadhesive microspheres (Formulation LM8) 
 
 
*Each reading is an average of three determinations 
  **Standard deviation of three determinations 
 
 
Time (hours) 
Cumulative 
Percentage drug  
Released* 
 
Standard Deviation** 
0 0 0 
1 38.18 0.91 
2 61.38 1.50 
3 79.31 1.12 
4 99.69 0.27 
5 - - 
6 - - 
7 - - 
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Figure 35:  In vitro release profile of Levofloxacin hemihydrate 
loaded mucoadhesive microspheres (Formulation LM8)             
(Bars represent mean of three values ± SD) 
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Table 16: In vitro release profile of Levofloxacin hemihydrate 
loaded mucoadhesive microspheres (Formulation LM9) 
 
 
*Each reading is an average of three determinations 
                  **Standard deviation of three determinations 
 
 
 
Time (hours) 
Cumulative Percentage 
drug  Released* 
 
Standard Deviation** 
0 0 0 
1 31.92 1.25 
2 49.17 0.89 
3 59.41 2.20 
4 67.17 2.57 
5 78.75 2.95 
6 85.77 1.73 
7 94.46 0.84 
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Figure 36:  In vitro release profile of Levofloxacin hemihydrate 
loaded mucoadhesive microspheres (Formulation LM9)                
(Bars represent mean of three values ± SD) 
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Table 17: In vitro release profile of levofloxacin hemihydrate 
loaded mucoadhesive microspheres (Formulation FA10) 
 
 
*Each reading is an average of three determinations 
                 **Standard deviation of three determinations 
 
 
 
Time (hours) 
Cumulative 
Percentage drug  
Released* 
 
Standard Deviation** 
0 0 0 
1 24.71 1.71 
2 41.40 1.68 
3 49.75 0.94 
4 55.76 2.42 
5 63.86 2.12 
6 71.12 2.17 
7 85.81 1.36 
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Figure 37:  In vitro release profile of Levofloxacin hemihydrate 
loaded mucoadhesive microspheres (Formulation LM10)                
(Bars represent mean of three values ± SD) 
 
 
 
 
 
 
0
10
20
30
40
50
60
70
80
90
100
0 1 2 3 4 5 6 7 8
C
u
m
u
la
ti
v
e
 %
 d
ru
g
 r
e
le
a
se
d
 
Time (hours) 
Formulation and evaluation of levofloxacin hemihydrate mucoadhesive microspheres for 
eradication of Helicobacter pylori  infection 
 
Department of Pharmaceutics 103            J.K.K. Nattraja College of Pharmacy 
 
 
 
 
 
 
Figure 38:  Effect of Eudragit RS 100 on the in vitro drug release 
characteristics of mucoadhesive microspheres of Levofloxacin 
hemihydrate in pH 1.2. (Bars represent mean of  
three values ± SD) 
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Figure 39:  Effect of Carbopol 974P on the in vitro drug release 
characteristics of mucoadhesive microspheres of Levofloxacin 
hemihydrate in pH 1.2. (Bars represent mean of  
three values ± SD) 
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Figure 40:  Effect HPMC K4M on the in vitro drug release 
characteristics of mucoadhesive microspheres of Levofloxacin 
hemihydrate in pH 1.2. (Bars represent mean of                            
three values ± SD) 
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Figure 41:  Comparativein vitro drug release characteristics of 
mucoadhesive microspheres of Levofloxacin hemihydrate in pH 
1.2. (Bars represent mean of three values ± SD) 
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IN VITRO RELEASE KINETIC ANALYSIS 
 
Table 18: In vitro release kinetic data of Levofloxacin 
hemihydrate loaded mucoadhesive microspheres 
F 
Code 
Zero order plot First order plot 
Higuchi 
plot 
Korsemeyer 
peppa’s plot 
K0 R2 K1 R2 R2 n R2 
LM1 ---* ---* ---* ---* 
 
---* ---** ---** 
LM2 18.9671 0.9954 -0.5729 0.8528 0.9978 ---** ---** 
LM3 16.5832 0.9986 -0.5338 0.7133 0.9901 ---** ---** 
LM4 12.9032 0.9951 -0.1819 0.9184 0.9942 0.6253 0.9998 
LM5 17.3134 0.9978 -0.6965 0.7763 0.9928 ---** ---** 
LM6 14.2145 0.9982 -0.3821 0.7060 0.9933 0.5945 0.9991 
LM7 13.4303 0.9964 -0.3052 0.7069 0.9943 0.6492 0.9988 
LM8 19.6230 0.9953 -0.7128 0.7819 0.9923 ---** ---** 
LM9 11.3107 0.9849 -0.1613 0.9677 0.9989 0.5528 0.9983 
LM10 09.8103 0.9919 -0.0954 0.9724 0.9945 0.5419 0.9975 
 
* Insufficient data points to apply kinetics due to rapid release profiles  
* *Insufficient data points to apply Korsmeyer-Peppas equation up to 70%. 
 
K0 – Zero order rate constant 
K1 – First order rate constant 
R2 – Regression coefficient 
         n- Diffusion exponent 
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 ACCELERATED STABILITY STUDIES 
 
Table 19: Accelerated stability data of Levofloxacin hemihydrate 
loaded mucoadhesive microspheres 
[Tested according to ICH Q1A(R2)] 
 
S.No Time (days) 
Mucoadhesive 
strength 
 (Mean ± SE) 
(n = 3) 
Drug 
content (%) 
(Mean ± SD) 
(n = 3) 
 
Drug release 
(%) 
(Mean ± SD) 
(n = 3) 
1 
Before storage 
(0 day) 
75.47±0.23 
25.85±0.34 
(37.04) 
99.62±0.23 
2 
30 days 
(After 
storage*) 
75.01±0.67 25.82±0.93 99.46±0.21 
3 
90 days 
(After 
storage*) 
74.66±0.86 25.78±0.51 99.28±0.18 
4 
180 days 
(After 
storage*) 
74.33±0.43 27.60±0.68 98.83±0.66 
 
 
*Storage at 40°C and 75% RH (n = 3). 
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Figure 42: Stability study in vitro dissolution profile of 
Levofloxacin hemihydrate loaded microspheres in pH1.2 (Data 
points represents mean ± SD) (n=3). 
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9. DISCUSSION OF RESULTS 
 
 
The mucoadhesive microsphere of levofloxacin hemihydrate was 
prepared by emulsification solvent evaporation technique. In this 
study, mucoadhesive polymers (HPMC K4M and carbopol 974P) were 
dispersed in matrix polymer (Eudragit RS 100.Studies had revealed 
that mucoadhesive microspheres adhere to the mucosal membrane 
more strongly when the mucoadhesive polymer was in dispersed 
state.173In this study, mucoadhesive polymers were dispersed in the 
microspheres in order to enhance mucoadhesion. Liquid paraffin and 
acetone were selected as outer and inner phases respectively.  Acetone 
with a dielectric constant of 20.7 was used as disperse (inner) phase 
because solvents with dielectric constants between 10–40 show poor 
compatibility with liquid paraffin.14,175In order to optimize 
mucoadhesive and controlled release property, the various 
combinations of HPMC K4M, carbopol 974P and Eudragit RS 100 
were used to prepare mucoadhesive microspheres [Table 1 & 2]. 
The standard curve of levofloxacin hemihydrate were plotted in 
0.1 N HCl (pH 1.2) at 370C. It was found to be linear for the 
concentration ranges from 01 µgm/ml to 10 µgm/ml (R2 =0.9961) for 
levofloxacin hemihydrate(Table 1& 25). 
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Percentage yield of microspheres 
The percentage yield of levofloxacin hemihydrate loaded 
microspheres was shown in Table 2. The percentage yield for 
levofloxacin hemihydrate loaded microspheres were found to be in the 
range of 39.20±1.62% to 92.40±1.32% and 37.53±1.43% to 
89.75±1.43% respectively. The microspheres yield increased with 
increase in the polymer concentration (P< 0.05). 
Drug content and encapsulation efficiency 
The effects of polymer concentration on the drug content and 
encapsulation efficiency of the prepared microspheres were shown in 
Table 3 &4.  Drug content of the levofloxacin hemihydrate loaded 
microspheres varied from 24.56±0.41% to 29.64±0.42%. The 
encapsulation efficiency of the prepared microspheres varied from 
52.31±1.16% to 86.33±0.67%. The encapsulation efficiency increased 
progressively by increasing the Eudragit RS100, HPMC K4M and 
carbopol 974P(P< 0.05). High concentration of matrix polymer solution 
increases viscosity of the polymer droplet and delays the drug 
diffusion within the polymer droplets.176Larger microspheres have a 
smaller total surface area per unit mass and, consequently, a lower 
amount of drugs diffuses in to liquid paraffin. As a result drug content 
of the larger microspheres was higher.177 
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Particle size analysis- Shape and surface characterization 
Viscosity of polymer solution is one of the most important factor 
related to formulation of microspheres.178 The polymer (Eudragit RS 
100) concentrations of 2%, 4%, 6% and 8% w/v were selected to 
determine optimum concentration of matrix polymer and also to study 
the effect of matrix polymer on drug release.  Flake formation was 
observed when Eudragit RS 100 concentration was used at 2 %, 
4%w/v, whereas maximum sphericity was observed at the 6 % w/v. 
Non-spherical microspheres were found when polymer concentration 
was used at 8% w/v. Therefore, 6% w/v of Eudragit RS 100 in acetone 
was found to be the optimum concentration for the polymer solution. 
The mean diameter of levofloxacin hemihydrate loaded microspheres 
were found to be in the range of 141.17±10.38μm to 543.91±18.94μm 
[Table 5]. The mean particle size increased with increasing 
concentration of Eudragit RS100, HPMC K4M carbopol 974P.  
 The reason for the increased particle size with the higher 
polymer concentration is that the viscosity of the dispersed phase. 
Viscosity of dispersed phase increases with increasing polymer 
concentration. When the viscosity of the dispersed phase increases, it 
will be more difficult to break up the droplets to a smaller size and 
larger droplet will be formed. Stirring efficiency was also reduced at 
higher polymer concentrations due to increased viscosity of the 
medium, resulting in an increase in the particle size.179If the amount 
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of polymer in each droplet if insufficient, the microspheres formed 
would not have enough strength to withstand the stirring, so it forms 
flakes. These factors might be the reason for changing particle size.  
In vitro evaluation of mucoadhesiveness 
The in vitro mucoadhesiveness study revealed that all the 
batches of prepared microspheres had good mucoadhesive property. 
Mucoadhesive property of the prepared microspheres varied from 
53.55±0.57% to 86.54±0.81%.[Table 6]. The mucoadhesive property 
slightly increased with increasing the Eudragit RS 100 concentration. 
It may be due to the mucoadhesive nature of Eudragit RS 100 
polymer.180A proportional increase in mucoadhesive strength of the 
formulation was observed with increase in the ratio of carbopol 974P 
and HPMC K4M. It was observed that mucoadhesive effect of HPMC 
K4M was less than carbopol 974P (P< 0.05).  It may be due to strong 
mucoadhesive nature of carbopol 974P than HPMC K4M at pH 1.2.In 
thisd study mucoadhesiveness was evaluated at pH 1.2. The lower 
degree of ionization of carboxyl groups of carbopol 974P in this acidic 
pH results stronger interaction with mucus. These effects were 
reﬂected in this study.  
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Compatibility studies  
DSC and FT-IR were performed on the raw materials and on the 
microspheres to detect interactions between the drug and the 
excipients.  
FTIR studies 
FTIR spectra were recorded for pure drug, drug-loaded 
microspheres and blank microspheres. According to the FTIR analysis 
results, excipients and active substances did not interact. The FTIR 
spectra of pure levofloxacin hemihydrate showed characteristic peaks  
for –COOH monomeric stretching and bonding at 3269 and 1045 cm-
1, alkanes –CH3 and aromatic rings 2846 and 1618 cm-
1,C=Ostretching vibration of the COOH group1721 cm-1andC– F835 
cm-1. All theabove peaks peaks of levofloxacin hemihydrate were also 
present in FTIR spectrum of drug-loaded microspheres with slight 
broadening and reduction in intensity in drug-loaded formulations 
that confirm the presence of drug in the polymer without 
anyinteraction. 
Differential Scanning Calorimeter (DSC) studies 
DSC spectra were recorded for pure drug, drug-loaded 
microspheres and blank microspheres. The endothermic peak of 
levofloxacin hemihydrateis observed at about 237.3 ºC [Figure 20]. 
Blank microspheres did not show any endothermic peaks because of 
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amorphous nature of Eudragit RS 100, HPMC K4M and carbopol 
974P[Figure 21]. No endothermic peak corresponding to the 
levofloxacin hemihydrate was observed in levofloxacin hemihydrate 
loaded microspheres [Figure 22]. The absence of detectable crystalline 
domains in the microspheres clearly indicates that the drug was 
molecularly dispersed in the microspheres.The absence of detectable 
crystalline domains in the microspheres clearly indicates that drug 
was molecularly dispersed in the microspheres.  
X-ray diffraction (XRD) studies 
In order to investigate the physical nature of the encapsulated 
drug, the powder X-ray diffraction technique was used. Diffraction 
patterns of Eudragit RS 100, HPMC K4M and Carbopol 974P, 
levofloxacin hemihydrate and drug loaded microsphere formulation 
were studied. 
 The powder XRD patterns of pure levofloxacin showed 
characteristic peaks, indicating that they are in a crystalline state. 
Eudragit RS 100, HPMC K4M and carbopol 974P showed patterns of 
amorphous substances [Figure 24-26]. The XRD patterns of the 
levofloxacin hemihydrate loaded microspheres were completely 
different from those of pure drug and showed no characteristic peaks 
[Figure 27]. This demonstrates that the drug was in an amorphous 
state in the microspheres. These results were in good agreement with  
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DSC studies. The loss of drug diffraction peaks in microspheres 
indicates a change in their crystal form during the process. 
In vitro dissolution studies 
 Dissolution test is a frequently used quality control method to 
evaluate drug release from oral dosage forms. Figure 28-37 shows the 
drug release profiles of levofloxacin hemihydrate loaded microspheres 
of various formulations. 
 An initial burst effect was observed in all the batches of 
microsphere formulations, which may be due to the drug being 
adsorbed or located near the surface of the microspheres. However, as 
the polymer swelling proceeds, the remaining drug was released at a 
slower rate. This bi-phasic pattern of drug release was a 
distinguishing feature of matrix diffusion systems.181The initial burst 
release effect was noticeably reduced with increase in polymer 
concentration. 
   A signiﬁcant decrease in the rate and extent of drug release 
was observed with the increase in polymer concentration 
microspheres).  This might be because of increase in the density of the 
polymer matrix and also an increase in the diffusional path length, 
which the drug molecules have to traverse.Increasing concentration of 
the Eudragit RS 100, drug release was decreased it might be due to 
increase ofthickness of gel diffusion layer. 
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 Drug release was retarded by increasing the proportion of 
carbopol 974P and HPMC K4M respectively. HPMC K4M significantly 
inﬂuenced the drug release than carbopol 974P (P< 0.05). This may be 
due to gelling nature of carbopol 974Pin 0.1 N HCl. Because of its 
nonionic nature HPMC K4M swellingwas not affected by pH variation.  
At pH 1.2, HPMC K4M may form viscous gel around the microspheres 
and control the drug release. 
 
0In vitro drug release and kinetics of release 
When the release data of levofloxacin hemihydrate loaded 
microspheres were plotted according to the first order equation, the 
formulations showed a fairly good linearity, with a R2 value of 0.7133-
0.9677[Table 18], whereas the same data, when plotted according to 
the zero order equation, improved the R2 value of 0.9839-0.9984 and 
0.9849-0.9986 [Table 18]. In our experiment, the in vitro release 
profiles of levofloxacin hemihydrate from all the formulations could at 
best  be  expressed by Higuchi’s equation,236 as the plots showed good 
linearity with R2 value of 0.9901-0.9989 [Table 18]. Good linearity was 
observed with the zero order equation. The slope of the regression line 
from the Higuchi plot indicates the rate of drug release and thus 
confirmed that the mode of release was diffusion, and to further 
confirm the diffusion mechanism, the data were fit into the 
Korsmeyer237et al., equation which showed high linearity with a 
comparatively high slope (n) value of 0.5419-0.5945for levofloxacin 
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hemihydrate loaded microspheres [Table 18]. This n-value indicated a 
coupling of diffusion and erosion mechanism. This type of drug 
release is called   as anomalous diffusion. This indicates that drug 
release from the microspheres follows a non-Fickian trend as reported 
earlier.182The presence of swelling polymers within the matrix 
structure might be responsible for the drug release controlled by more 
than one process. Thus, with regard to release kinetics, the data best 
fits in the Higuchi model and showed zero order release with a non-
Fickian diffusion mechanism. The results showed that when an 
appropriate blend of these polymers was used, the drug release 
became more uniform in its kinetic approach towards zero order. 
Selection of best formulation 
The normal mucus turnover rate is 4–6 hours in rats 183-
185,186and likely similar values in humans.187The mucus turnover 
rather than the mucus-polymer interaction that controls the 
presenceof mucoadhesive formulations through theGIT.188Based on 
the mucus turnover rate and dissolution time, formulations LM 6 
(formulations consisting of 6 % w/v Eudragit RS, 1.5 % w/v carbopol 
974P and 1% w/v HPMC K4M) were selected as best formulations. 
Accelerated stability studies LM 6. 
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Accelerated stability testing according to ICH Q1A (R2)  
The optimized formulation (FA6 & FC6) were stored in a stability 
chamber (Remi CHM- 10 S®, India) at 40 ± 2°C and at a humidity of 
75 ± 5% RH for 6 months and observed for the drug content, 
mucoadhesiveness and in vitro drug release on 0, 30, 90, and 180 
days [Table 19]. The zero time samples were used as controls. No 
remarkable changes were observed in drug content, 
mucoadhesiveness and in vitro drug release in stability studies [Figure 
42]. 
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10. CONCLUSION 
The aim of the present research work was to formulate and 
evaluate mucoadhesive microspheres of levofloxacin hemihydrate 
using the mucoadhesive polymers (carbopol 974P and HPMC K4M for 
H. pylori eradication. These two polymers (carbopol 974P   and HPMC 
K4M) act as complimentary to each other in that carbopol 974P 
increases the mucoadhesion and HPMC K4M other hand helps to 
control drug release. From all of the experiments performed, it can be 
concluded that the developed mucoadhesive polymers can be 
successful in the effective for treatment of H. pylori infection. The 
developed  mucoadhesive polymers may decrease the short                                                                                                                             
comings of conventional drug delivery systems. It can also deliver the 
antimicrobial effect to the infected mucosal area. It is possible that 
mucoadhesive polymers with uniform gastric distribution can 
targetthe H. pylori-infected sites more effectively and could optimize 
antibiotic monotherapy of H. pylori, which could be of definite 
therapeutic benefit. Further more, inorder to confirm the efficiency of 
developed formulations, In-vivo buoyancy and pharmacokinetic 
studies are necessary. 
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